. In this section, unless otherwise specified, references to we, our, us and our company refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (Gyre Pharmaceuticals). Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our m...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001193125-26-106251 | EDGAR | 126K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040279 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037242 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001564590-23-004830 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-012877 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010823 | EDGAR | — |
| 2020-02-20 | 2019-12-31 | 0001564590-20-005546 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001564590-19-006879 | EDGAR | — |
| 2018-03-19 | 2017-12-31 | 0001564590-18-006216 | EDGAR | — |
| 2017-03-08 | 2016-12-31 | 0001564590-17-003722 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001193125-25-272383 | EDGAR | 31K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106644 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068089 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126306 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096159 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058642 | EDGAR | — |
| 2023-10-26 | 2023-09-30 | 0000950170-23-055695 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042218 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001564590-23-007276 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037555 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029487 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001564590-22-018775 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001140361-26-010654 | EDGAR | 1K words |
| 2026-03-12 | 0001140361-26-009115 | EDGAR | — |
| 2026-03-12 | 0001193125-26-102700 | EDGAR | — |
| 2026-03-02 | 0001140361-26-007249 | EDGAR | — |
| 2026-01-05 | 0001140361-26-000253 | EDGAR | — |
| 2025-11-07 | 0001193125-25-270524 | EDGAR | — |
| 2025-09-10 | 0001140361-25-034506 | EDGAR | — |
| 2025-08-22 | 0001140361-25-032295 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106525 | EDGAR | — |
| 2025-06-06 | 0001140361-25-021612 | EDGAR | — |
317 total filings indexed. 285 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001124105 |
| Ticker | GYRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gyretx.com |
| Listed | 2023-10-31 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report